Dyne Therapeutics, Inc. (DYN) Financials

DYN Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 994.0 million 291.9 million
March 31, 2026 1.1 billion 214.9 million
Dec. 31, 2025 1.2 billion 214.8 million
Sept. 30, 2025 867.1 million 175.3 million

DYN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -131.8 million 15.0 million
March 31, 2026 -145.1 million 13.1 million
Dec. 31, 2025 -112.3 million 11.2 million
Sept. 30, 2025 -110.0 million 11.1 million

DYN Net Income

No data available :(

DYN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 898.5 million 14.5 million 19.9 million
March 31, 2026 972.2 million 14.3 million 19.3 million
Dec. 31, 2025 1.1 billion 15.3 million 20.3 million
Sept. 30, 2025 791.9 million 99.1 million 21.3 million

DYN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 165.5 million
March 31, 2026 165.0 million
Dec. 31, 2025 128.4 million
Sept. 30, 2025 141.8 million

DYN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1.5 million 152.2 million 29.5 million -
March 31, 2026 221000 100.9 million 24.4 million -
Dec. 31, 2025 484000 95.4 million 20.7 million -
Sept. 30, 2025 19.2 million 97.2 million 16.7 million -

DYN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 550000
Dec. 31, 2025 - 521000
Sept. 30, 2025 - -

DYN

Price: $15.29

52 week price:
13.73
27.31

Earnings Per Share: -3.28 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 169300

Ebitda: 950.0 million

Market Capitalization: 2.9 billion

Links: